Trial Profile
A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Proof of concept; Therapeutic Use
- 10 Apr 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 10 Apr 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 04 Mar 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.